Acids and Synthetic Reagents

<p>Applications TAE 684 is a potent, selective, and efficacious inhibitor of NPM-ALK, a fusion protein that is a key regulator of oncogenic events that drives the survival and proliferation of anaplastic large-cell lymphomas. Potent ALK inhibitor<br>References Schoenherr, C., et al.: Oncogene., 31, 5193 (2012); Tanizaki, J., et al.: Clin. Cancer. Res., 18, 6219 (2012); Heuckmann, J.M., et al.: Clin. Cancer. Res., 18, 4682 (2012);<br></p>

<p>Applications 4-Methoxybenzenemethanamine is used in the synthesis of COX2 inhibitors based on a pyrimidine scaffold. Also used in the preparation of SIRT1 inhibitors. Used in anti-cancer treatments.<br> Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package<br>References Tietz, O. et al.: Org. Biomol. Chem., Eur. J. Med. Chem., 69, 125 (2013);<br></p>

<p>Applications Dimethyl Acetylenedicarboxylate is a biocide that is added to biodiesels to inhibit and remove microbial growth. It can rapidly penetrate the skin and cause aberrations in the activities of the glycogenic, lipogenic, and tricarboxylic acid metabollic pathways. It also causes delayed and pain-free dermal burns.<br> Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package<br>References Poon, R., et al.: Arch. Toxicol., 85(11), 1419-1427 (2011); Klain, George J., et al.: Fund. Appl. Toxicol., 10(4), 730-5 (1988); Slovak, A. J. M., et al.: Contact Dermatitis, 11(1), 29-30 (1984)<br></p>

<p>Applications 2,3-Dichloroquinoxaline is a dichlorinated quinoxaline derivative with antimicrobial activity. 2,3-Dichloroquinoxaline is used in the preparation of quinoxaline derivatives of cancer chemopreventive activity.<br> Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package<br>References Metzner, J. et al.: Pharmazie, 36, 368 (1981); Galal, S.A&gt; et al.: Eur. J. Med. Chem., 46, 327 (2011);<br></p>

<p>Applications Semisynthetic camptothecin which inhibits DNA topoisomerase I. Prodrug of 9-aminocamptothecin. Antineoplastic.<br>References Stehlin, J.S., et al.: Int. J. Oncol., 14, 821 (1999), Verschraegen, C.F., et al.: Curr. Opin. Oncol. Endocr. Metab. Invest. Drugs, 1, 184 (1999),<br></p>

<p>Applications NE-100 is a potent and selective σ1 receptor antagonist.<br>References Sabino, V., et al.: Psychopharmacology, 205, 327 (2009); Kunitachi, S., et al.: Brain Res., 1279, 189 (2009)<br></p>

<p>Applications Tetramethylammonium Bromide (cas# 64-20-0) is a useful research chemical.<br></p>

<p>Applications 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one inhibits neurite outgrowth and causes neurite retraction in PC12 cells independently of soluble guanylyl cyclase.<br>References Lee, H.G., et al.: J. Neurosci. Res., 87 269 (2009),<br></p>

<p>Applications tert-Butyl Methylcarbamate is an substituent in the synthetic preparation of PF-06463922, a macrocyclic inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1).<br>References Johnson, T. W., et al.: J. Med. Chem., 57, 4720 (2014);<br></p>

<p>Applications 4-Chloro-3-(trifluoromethyl)phenyl isocyanate is used as a reagent to synthesize pyrimidinylaminobenzene derivatives, compounds that have antiproliferative activity against melanoma cell lines. 4-Chloro-3-(trifluoromethyl)phenyl isocyanate is also used to synthesize α-thymidine analogues that act as antimalarial agents.<br> Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package<br>References Cui, H., et al.: J. Med. Chem., 55, 10948 (2012); Kim, H., et al.: Bull. Kor. Chem. Soc., 34, 2311 (2013)<br></p>

<p>Applications MDL 29951 is an allosteric inhibitor of the enzyme fructose 1,6-bisphosphatase.<br>References Wright, S., et. al.: Bioorg. Med. Chem. Lett., 13, 2055 (2003)<br></p>

<p>Applications An intermediate for polycyclic indazole derivatives that are ERK inhibitors.<br>References Orjales, A., et al.: J. Med. Chem., 46, 5512 (2003), Mariappan, P., et al.: J. Eur. Urology., 51, 67 (2007), Hughes, J., et al.: Bioorg. Med. Chem. Lett., 18, 4872 (2008), Kielbasa, W., et al.: Drug Metab. Dispos., 37, 137 (2009),<br></p>